Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence

The global prevalence and incidence of metabolic dysfunction‐associated fatty liver disease (MAFLD), including its progressive form metabolic dysfunction‐associated steatohepatitis (MASH), are steadily rising, making them the most common chronic liver diseases worldwide. However, therapeutic options for MAFLD are currently limited. Glucolipid dysregulation drives MAFLD pathogenesis through intertwined glucose metabolic imbalance and lipid accumulation. Patients with type 2 diabetes mellitus (T2DM) are particularly prone to developing MASH and are at a higher risk of progressing to cirrhosis and hepatocellular carcinoma. The coexistence of MAFLD and T2DM correlates with clinical prognosis and elevates the risk of extrahepatic complications. Given the close association between MAFLD and T2DM, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), which have been approved for the treatment of T2DM and obesity, were the first to be investigated in patients with MAFLD/MASH. Recently, beyond GLP‐1RAs, novel combination agents integrating glucose‐dependent insulinotropic peptide receptor (GIPR) and/or glucagon receptor (GCR) agonists have also been explored. A large number of phase II randomized clinical trials have demonstrated significant improvements in body weight, insulin resistance, and liver parameters. Thus, GLP‐1RAs and dual/triple agonists are promising for MAFLD/MASH, especially in those with obesity or T2DM. This study explores mechanisms and clinical evidence of incretin‐based therapies for MAFLD by targeting its core pathogenesis—glucolipid disorders. With growing evidence, it also forecasts the broad clinical prospects on MAFLD treatment.